A Response to "Letter to the Editor Regarding 'Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison'". - Ständer S; Pinter A; Hougeir FG; Guyot P; Xu Y; Praestgaard AH; Freemantle N; Rossi AB; Bégo-Le-Bagousse G; Wang Z; Noonan K; Bastian M (Dermatology and therapy, 2026)